Search Results - "Wisinski, K B"

Making Informed Choices On Incorporating Chemoprevention into carE (MiCHOICE, SWOG 1904): Design and methods of a cluster randomized controlled trial by Crew, K.D., Anderson, G.L., Arnold, K.B., Stieb, A.P., Amenta, J.N., Collins, N., Law, C.W., Pruthi, S., Sandoval-Leon, A., Bertoni, D., Grosse Perdekamp, M.T., Colonna, S., Krisher, S., King, T., Yee, L.D., Ballinger, T.J., Braun-Inglis, C., Mangino, D., Wisinski, K.B., DeYoung, C.A., Ross, M., Floyd, J., Kaster, A., Vander Walde, L., Saphner, T., Zarwan, C., Lo, S., Graham, C., Conlin, A., Yost, K., Agnese, D., Jernigan, C., Hershman, D.L., Neuhouser, M.L., Arun, B., Kukafka, R.

“…Women with atypical hyperplasia (AH) or lobular carcinoma in situ (LCIS) have a significantly increased risk of breast cancer, which can be substantially…”
Get full text

AZD8186, a potent and selective inhibitor of PI3Kβ/δ, as monotherapy and in combination with abiraterone acetate plus prednisone (AAP), in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) by de Bono, J.S., Hansen, A., Choudhury, A.D., Cook, N., Heath, E.I., Higano, C., Linch, M., Martin-Liberal, J., Rathkopf, D.E., Wisinski, K.B., Barry, S., de Bruin, E., Brugger, W., Colebrook, S., Klinowska, T., Moschetta, M., Mortimer, P.G.S., Siu, L.L., Shapiro, G.

Get full text

Fragmentomic analysis of circulating tumor DNA-targeted cancer panels by Helzer, K.T., Sharifi, M.N., Sperger, J.M., Shi, Y., Annala, M., Bootsma, M.L., Reese, S.R., Taylor, A., Kaufmann, K.R., Krause, H.K., Schehr, J.L., Sethakorn, N., Kosoff, D., Kyriakopoulos, C., Burkard, M.E., Rydzewski, N.R., Yu, M., Harari, P.M., Bassetti, M., Blitzer, G., Floberg, J., Sjöström, M., Quigley, D.A., Dehm, S.M., Armstrong, A.J., Beltran, H., McKay, R.R., Feng, F.Y., O’Regan, R., Wisinski, K.B., Emamekhoo, H., Wyatt, A.W., Lang, J.M., Zhao, S.G.

“…The isolation of cell-free DNA (cfDNA) from the bloodstream can be used to detect and analyze somatic alterations in circulating tumor DNA (ctDNA), and…”
Get full text

833PAZD8186, a potent and selective inhibitor of PI3Kβ/δ, as monotherapy and in combination with abiraterone acetate plus prednisone (AAP), in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) by de Bono, J S, Hansen, A, Choudhury, A D, Cook, N, Heath, E I, Higano, C, Linch, M, Martin-Liberal, J, Rathkopf, D E, Wisinski, K B, Barry, S, de Bruin, E, Brugger, W, Colebrook, S, Klinowska, T, Moschetta, M, Mortimer, P G S, Siu, L L, Shapiro, G

Get full text

Abstract OT1-02-01: Phase I trial of bicalutamide and ribociclib in androgen receptor-positive triple negative breast cancer by Sharifi, M, Wisinski, KB, Burkard, ME, Tevaarwerk, AJ, Tamkus, D, Chan, N, Truica, C, Danciu, O, Hoskins, K, O'Regan, RM

“…Background: To date, the use of anti-androgens in the subset of triple negative breast cancers (TNBC) that express androgen receptor (AR) has shown modest…”
Get full text

Abstract SP012: Convergent evolution of resistance pathways during early stage breast cancer treatment with combination cell cycle (CDK) and endocrine signaling inhibitors by Griffiths, JI, Chen, J, Cosgrove, PA, O'Dea, A, Sharma, P, Ma, CX, Trivedi, M, Kalinsky, K, Wisinski, KB, O'Reagan, R, Makhoul, I, Spring, LM, Bardia, A, Adler, FR, Cohen, AL, Chang, JT, Khan, QJ, Bild, AH

“…Combining cyclin-dependent kinase (CDK) inhibitors with endocrine therapy improves outcomes for metastatic estrogen receptor positive (ER+), HER2 negative,…”
Get full text

Predictors of Willingness to Participate in Window-of-Opportunity Breast Trials by Wisinski, Kari B, Faerber, Adrienne, Wagner, Stephanie, Havighurst, Thomas C, McElroy, Jane A, Kim, Kyungmann, Bailey, Howard H

“…We conducted a pilot survey to evaluate breast cancer patients' willingness to participate in a preoperative chemoprevention (ie, window-of-opportunity) study…”
Get full text

Abstract OT3-02-06: A phase 1 study of BMN 673 in combination with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782) by Mullvain, JA, Leal, T, Eickhoff, J, Kolesar, JM, Liu, G, DiPaola, RS, Wisinski, KB

“…Background: Poly(ADP-ribose) polymerase (PARP) enzymes are involved in DNA repair and are activated by DNA strand breaks. DNA damage from carboplatin has been…”
Get full text

Abstract OT3-01-03: A phase I trial of the safety and immunogenicity of a DNA plasmid based vaccine (WOKVAC) encoding epitopes derived from three breast cancer antigens (IGFBP2, HER2, and IGF1R) in patients with breast cancer by Childs, JS, Higgins, DM, DeShong, K, Heckman-Stoddard, BM, Wojtowicz, ME, Stanton, SE, Bailey, HH, Wisinski, KB, Disis, ML

“…Background: Three proteins insulin like growth factor binding protein 2 (IGFBP2), human epidermal growth factor receptor 2 (HER2), and insulin like growth…”
Get full text

Abstract P5-13-03: Prospective study of work limitations in breast cancer patients (pts) undergoing curative chemotherapy (CTx) by Tevaarwerk, AJ, Buhr, KA, Conkright, W, Onitilo, A, Robinson, E, Hegeman, R, Ahuja, H, Kwong, RW, Nanad, R, Dennee, A, Koehn, T, Burkard, ME, Wisinski, KB, Wiegmann, DA, Sesto, ME

“…This abstract was withdrawn by the authors…”
Get full text

Abstract P3-02-11: Screening Magnetic Resonance Imaging (MRI) of the breast in women at increased lifetime risk for breast cancer: A retrospective single institution study by Ehsani, S, Strigel, R, Pettke, E, Wilke, L, Szalkucki, L, Tevaarwerk, AJ, Wisinski, KB

“…Background: Multiple factors are associated with an increased lifetime risk of breast cancer, including inheritance of an abnormal BRCA 1/2 gene, history of…”
Get full text

Abstract P3-12-10: Feasibility of four cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: A Wisconsin oncology network study by Wisinski, KB, Burkard, ME, Njiaju, U, Donohue, S, Hegeman, R, Stella, A, Mansky, P, Shah, V, Goggins, T, Qamar, R, Dietrich, L, Kim, K, Traynor, A, Tevaarwerk, A

“…Background: Dose-dense therapies have had a major impact on reducing toxicity and improving outcomes in breast cancer. A combination of docetaxel plus…”
Get full text

P4-11-21: A Retrospective Analysis of Women at Increased Lifetime Risk for Breast Cancer: Referral Patterns to Subspecialty Providers, Recommendations and Outcomes by Ehsani, S, Tevaarwerk, A, Wilke, L, Neuman, H, Beckman, C, Becker, J, Stettner, A, Strigel, R, Szalkucki, L, Burkard, M, Wisinski, KB

“…Background: Inheritance of an abnormal BRCA 1/2 gene, a family history of breast cancer (BrCa), or a personal history of lobular carcinoma in situ (LCIS),…”
Get full text

Abstract P6-12-02: Use of cytochrome P450 interacting medications in the setting of adjuvant therapy for breast cancer by Njiaju, UO, Kolesar, JM, Johnston, SA, Eickhoff, JC, Osterby, KR, Poggi, LE, Tevaarwerk, AJ, Millholland, RJ, Oliver, KA, Heideman, JL, Wisinski, KB

“…Background: In the current era of personalized medicine, oral targeted therapies are increasingly used in cancer treatment. In breast cancer, oral…”
Get full text

Abstract P2-11-15: Development of a web-based survey tool to assess change in breast cancer (BrCa) survivor knowledge after receipt of cancer treatment summary and survivorship care plan (SCP) by Custer, JL, Rocque, GB, Wisinski, KB, Jones, NR, Donohue, S, Koehn, TM, Champeny, TL, Terhaar, AR, Chen, KB, Peck, KA, Tun, MT, Wiegmann, DA, Sesto, ME, Tevaarwerk, AJ

“…Intro: The Institute of Medicine advocates survivorship care plans (SCPs) as tools to improve coordination of care by improving survivor knowledge of follow-up…”
Get full text

P5-18-12: Perception, Practice and Toxicity of Adjuvant Treatment of HER2+ Breast Cancer in Wisconsin by Rocque, GB, Onitilo, AA, Engel, JM, Pettke, EN, Boshoven, AM, Zhang, S, Kim, KM, Rishi, S, Waack, B, Wisinski, KB, Tevaarwerk, AJ, Burkard, ME

“…INTRODUCTION: Multiple trastuzumab-containing (neo)adjuvant regimens are used for HER2+ BrCa, but the experience with these regimens in routine practice is not…”
Get full text